After posting positive top-line data in August from its phase III ENHANCE-2 study of ensifentrine for treating chronic obstructive pulmonary disease (COPD), Verona Pharma plc now has positive results from the companion phase III study. The ENHANCE-1 trial of ensifentrine as a COPD maintenance treatment hit its primary and key secondary endpoints, prompting the company to say it plans to submit an NDA for the treatment to the U.S. FDA sometime in the first half of 2023.
Roche has synthesized pyruvate dehydrogenase kinase 1 (PDK1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus, psoriasis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and cancer.
Ocean University of China has identified novel benzotropone derivatives acting as phosphodiesterase 4 (PDE4) and/or cAMP and cAMP-inhibited cGMP 3ʹ,5ʹ-cyclic phosphodiesterase 10A (PDE10A) inhibitors reported to be useful for the treatment of allergy, inflammatory, neurological and cardiovascular diseases.
Humanwell Healthcare (Group) Co. Ltd. has synthesized dihydropyrimidoisoquinolinone derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, metabolic and endocrine disorders, among others.
Humanwell Healthcare (Group) Co. Ltd. has disclosed G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, autoimmune and metabolic diseases, among others.
Researchers from Jagiellonian University presented the discovery of novel multifunctional inhibitors of phosphodiesterases (PDEs) and transient receptor potential ankyrin 1 (TRPA1) antagonists as potential therapeutic candidates for the treatment for chronic airway disorders.
Researchers from GSK plc presented the discovery and preclinical characterization of novel potent and selective inhaled phosphatidylinositol 4-kinase β (PI4Kβ) inhibitor being developed for the treatment of human rhinovirus (HRV)-induced chronic obstructive pulmonary disease (COPD) exacerbations.
A metabolite derived from the airway microbiome, indole-3-acetic acid (IAA), could become a potential therapeutic candidate for chronic obstructive pulmonary disease (COPD). Researchers at South China Normal University (SCNU) have shown how IAA prevents lung function decline by reducing inflammation, apoptosis and emphysema through IL-22 in the interaction between macrophages and alveolar epithelial cells.
Patients with chronic obstructive pulmonary disease (COPD) may soon have a new way to better manage their health without increasing doctor visits. Nuvoair AB reported that a trial in two U.S. locations showed that 80% of participants with COPD experienced a reduction in hospitalizations as well as improvement in quality of life using the company's integrated digital app and counseling program.
